BAY94-9027
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for BAY94-9027, covering 2018-12-06 to 2025-07-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood [Phase 3]